Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors

Nature Biotechnology

Volumn 22, Issue 6, 2004, Pages 701-706

  Smith Jones, Peter M ^a   Solit, David B ^a   Akhurst, Timothy ^a   Afroze, Farzana ^a   Rosen, Neal ^a   Larson, Steven M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEGRADATION; DRUG DOSAGE; ENZYME INHIBITION; MEDICAL IMAGING; PHARMACODYNAMICS; SIGNALING; TUMORS;

ANIMAL TUMORS; CLINICAL TRIAL; THERAPEUTIC;

IMAGING TECHNIQUES;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 17 ALLYLAMINOGELDANAMYCIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GALLIUM; GALLIUM 58; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; IMMUNOGLOBULIN F(AB')2 FRAGMENT; PROTEIN; PROTEIN INHIBITOR; RETINOIC ACID; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; ONCOGENE NEU; PHARMACODYNAMICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR MODEL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZOQUINONES; BLOTTING, WESTERN; CELL LINE, TUMOR; COPPER RADIOISOTOPES; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOBLOTTING; IMMUNOGLOBULIN FAB FRAGMENTS; INDIUM RADIOISOTOPES; ISOTOPE LABELING; LACTAMS, MACROCYCLIC; MICE; MICE, NUDE; MOLECULAR PROBE TECHNIQUES; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, ERBB-2; RIFABUTIN; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA;

EID: 2542643923     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt968     Document Type: Article

References (30)

1. Ebert, A.D. et al. Expression and function of EGF-related peptides and their receptors in gynecological cancer-from basic science to therapy. J. Recept. Signal Transduct. Res. 20, 1-46 (2000).
2. Yee, K.W. & Keating, A. Advances in targeted therapy for chronic myeloid leukemia. Expert Rev. Anticancer Ther. 3, 295-310 (2003).
3. Slack, J.L. & Rusiniak, M.E. Current issues in the management of acute promyelocytic leukemia. Ann. Hematol. 79, 227-238 (2000).
4. Paterson, S.C., Smith, K.D., Holyoake, T.L. & Jorgensen, H.G. Is there a cloud in the silver lining for imatinib? Br. J. Cancer 88, 983-987 (2003).
5. Mandelli, F., Avvisati, G. & Lo Coco, F. Advances in the understanding and management of acute promyelocytic leukemia. Rev. Clin. Exp. Hematol. 6, 60-71 (2002).
6. Ritter, C.A. & Arteaga, C.L. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin. Oncol. 30 (suppl. 1), 3-11 (2003).
7. Baselga, J. & Hammond, L.A. HER-targeted tyrosine-kinase inhibitors. Oncology. 63 (suppl. 1), 6-16 (2002).
8. Nahta, R., Hortobagyi, G.N. & Esteva, F.J. Growth factor receptors in breast cancer: potential for therapeutic intervention. Oncologist 8, 5-17 (2003).
9. Ranson, M. & Sliwkowski, M.X. Perspectives on anti-HER monoclonal antibodies. Oncology63 (suppl. 1), 17-24 (2002).
10. Sledge, G.W. Jr. Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer. Semin. Oncol. 30 (suppl. 3), 19-21 (2003).
11. Khalil, M.Y., Grandis, J.R. & Shin, D.M. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer. Expert Rev. Anticancer Ther. 3, 367-380 (2003).
12. Anido, J. et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin. Cancer Res. 9, 1274-1283 (2003).
13. Herbst, R.S. & Kies, M.S. ZD1839 (Iressa) in non-small cell lung cancer. Oncologist. 7 (suppl. 4), 9-15 (2002).
14. Neckers, L. Heat shock protein 90 inhibition by 17-allylamino-17-demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer. Clin. Cancer Res. 8, 962-966 (2002).
15. Neckers, L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 8 (suppl.), S55-61 (2002).
16. Solit, D. et al. 17-allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res. 8, 986-993 (2002).
17. Solit, D.B., Basso, A.D., Olshen, A.B., Scher, H.I. & Rosen, N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res. 63, 2139-2144 (2003).
18. Rasey, J.S. et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int. J. Radiat. Oncol. Biol. Phys. 36, 417-428 (1996).
19. Rockoff, S.D., Goodenough, D.J. & McIntire, K.R. Theoretical limitations in the immunodiagnostic imaging of cancer with computed tomography and nuclear scanning. Cancer Res. 40(8 Pt 2), 3054-3058 (1980).
20. Vogel, C.L. & Franco, S.X. Clinical experience with trastuzumab (herceptin). Breast J. 9, 452-462 (2003).
21. Cohen, S.J. et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J. Clin. Oncol. 21, 1301-1306 (2003).
22. Hidalgo, M. & Bloedow, D. Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva). Semin. Oncol. 30 (suppl. 7), 25-33 (2003).
23. Harris, L.N. et al. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J. Clin. Oncol. 19, 1698-1706 (2001).
24. Maulik, G. et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin. Cancer Res. 8, 620-627 (2002).
25. Zheng, F.F. et al. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases. Cancer Res. 60, 2090-2094 (2000).
26. Qiang, Y.W., Yao, L., Tosato, G. & Rudikoff, S. Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells. Blood 103, 301-308 (2004).
27. Signoretti, S. et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl. Cancer Inst. 92, 1918-1925 (2000).
28. Scher, H.I. et al. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin. Cancer Res. 1, 545-550 (1995).
29. Arteaga, C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin. Oncol. 30 (suppl. 7), 3-14 (2003).
30. Smith-Jones, P.M. et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. Cancer Res. 60, 5237-5243 (2000).